Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases

Costa, Luciano J.; Xavier, Ana C.; Wahlquist, Amy E.; Hill, Elizabeth G.

doi:10.1182/blood-2012-12-475558

Cited by 79 publications

(70 citation statements)

References 20 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study did not find a statistically significant impact of advancing age on survival among patients treated with dose-intense chemotherapy regimens. This is similar to one recent study [Todeschini et al 2012], but contrasts with several other studies, including a systematic review [Kelly et al 2009] and two recent SEER registry studies [Castillo et al 2013;Costa et al 2013] which found poorer outcomes with advancing age. In the current study, only patients who received dose-intense chemotherapeutic regimens were included; thus, there was no age-associated difference in survival among patients deemed fit to receive dose-intense chemotherapy.…”

Section: Discussioncontrasting

confidence: 53%

Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers

Wildes

Farrington

Yeung

et al. 2013

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Background: Burkitt lymphoma (BL) is a rare, highly aggressive B-cell malignancy treated most successfully with brief-duration, high-intensity chemotherapeutic regimens. The benefit of the addition of rituximab to these regimens remains uncertain. We sought to examine the effectiveness of chemotherapy with and without rituximab in patients with BL. Methods: This study is a retrospective cohort study of all adult patients with BL diagnosed and treated with modern, dose-intense chemotherapeutic regimens from 1998-2008 at two tertiary care institutions. All cases were confirmed by application of WHO 2008 criteria by hematopathologists. Medical records were reviewed for patient-, disease-, and treatmentrelated factors as well as treatment response and survival. Factors associated with survival were analyzed using Cox proportional hazards modeling. Results: A total of 35 patients were analyzed: 18 patients received rituximab with chemotherapy (R-chemo) and 17 received chemotherapy (chemo) alone. The median age was 42 (range 20-74 years); 57% were male; 71% had Ann Arbor Stage IV disease; 33% had central nervous system involvement; 78% had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. R-chemo was associated with significantly longer overall survival (OS) than chemo alone (5-year OS 70% and 29%, respectively, p = 0.040). On multivariate regression analysis, poor performance status and central nervous system involvement were associated with poorer survival. Conclusions: The addition of rituximab to chemotherapy was associated with improved OS in patients with Burkitt lymphoma. Poor performance status and central nervous system involvement were prognostically significant on multivariate analysis.

show abstract

Section: Discussioncontrasting

confidence: 53%

Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers

Wildes

Farrington

Yeung

et al. 2013

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

show abstract

“…Considering that the majority of relapses occur during the first year after completion of treatment in BL we do not expect a relapse after almost 5 years remaining in complete remission. The results of the studies published by Costa et al [9] and Intermesoli et al [10] are in parallel with this opinion showing a high survival and a low relapse rate after 4 years in our patient's age group. However, there are no published cases of BL successfully treated with surgery alone.…”

Section: Dear Editorsupporting

confidence: 89%

Complete Remission of Burkitt Lymphoma After Surgical Excision: A Case Report

Beköz

Kantarcıoğlu

Tecimer

et al. 2016

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Burkitt lymphoma (BL) is a highly aggressive B cell non-Hodgkin lymphoma that has a high proliferation rate. The prognosis for BL is generally favorable, with cure rate of 75-90 % with modern chemoimmunotherapy regimens. Prompt administration of multiagent immunochemotherapy regimens is critical, because BL is almost always fatal if left untreated. Nevertheless here we report a case of BL that is still in complete remission after more than 4 years without any further treatment after surgical excision of the involved lymph node.

show abstract

“…However, it is unclear whether the source of the disparity is a lack of healthcare access, refusal of therapy or a distinct metabolism of chemoimmunotherapy in such demographic. Another population-based study using the SEER database that included pediatric patients also confirms our findings of poor outcomes in black patients with BL [10]. Furthermore, other epidemiological studies have associated blacks with worse outcomes in diffuse large B cell and Hodgkin lymphoma [11,12].…”

supporting

confidence: 72%

Improving the accuracy in prognosis for Burkitt lymphoma patients

Castillo

Nadeem

2013

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases

Abstract: Key Points Survival of patients with BL improved substantially in the United States during the past decade, mainly among young adults. Survival of patients with BL remains relatively low, particularly for older and black patients, identifying an unmet need.

Cited by 79 publications

References 20 publications

Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers

Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers

Complete Remission of Burkitt Lymphoma After Surgical Excision: A Case Report

Improving the accuracy in prognosis for Burkitt lymphoma patients

Contact Info

Product

Resources

About